Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Summary

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

Timeline

Start

2025-04-14

Primary completion

2027-12

Completion

2028-06

Drugs

Indications